You are in : All News > Probi and Ipsen Sign Primary Care Distribution Agreement for Probiotic LP299V

    Probi and Ipsen Sign Primary Care Distribution Agreement for Probiotic LP299V

    26 Apr 2016 --- Global biotechnological group Ipsen and Swedish bioengineering company Probi jointly announce the signature of a license and supply agreement for the commercialization of Probi’s probiotic strain Lactobacillus plantarum 299v (LP299V).

    The agreement covers 18 countries, primarily within EU and emerging markets. This clinically-documented probiotic with patents in the gastro-intestinal field is expected to complement Ipsen’s strong medical portfolio in gastroenterology. From Probi’s perspective it could become one of the the largest distribution agreements so far and is of high strategic importance for both companies.

    Under this new agreement, Probi will supply bulk LP299V capsules and Ipsen will be responsible for packaging, marketing and selling the product. The product is planned to be marketed primarily through pharmacies. It is expected to be launched in the first half of 2017 as a food supplement in the European markets, and then, in other key markets such as Russia and China, depending on regulatory approval.
    Probi’s dietary supplement contains a single species of Lactobacillus that was found by Swedish researchers at Lund University. Probi’s dietary supplement has strong clinical evidences for reduction of signs and symptoms of Irritable Bowel Syndrome (IBS) in adults.
    arrow
    Many of the 18 markets have high growth potential, with an option to include additional countries. The product will be marketed under Ipsen’s key brand and Probi’s trademark LP299V.
    Marc de Garidel, Chairman and Chief Executive Officer of Ipsen stated: “Ipsen is delighted to enter the field of probiotics with a very well-recognized and R&D focused company such as Probi.”
    “This partnership is fully aligned with our strategy to strengthen our portfolio in the field of gastroenterology and expand into probiotics.”
    Jean Fabre, Executive Vice President of Primary Care added: “This agreement will help sustain Ipsen’s Primary Care growth and accelerate transition to the OTx[1] model.”

    “The product has strong medical endorsement that will perfectly fit with our expertise and leverage our capabilities towards physicians and pharmacists in many countries.”
    Commenting on this partnership, Peter Nählstedt, Chief Executive Officer of Probi noted: “We have found a perfect match with Ipsen – a very well respected pharmaceutical company with high growth ambitions and strong brands in the gastrointestinal field.”
    “Through its extensive organization we expect to enter many new markets with LP299V, which will strengthen Probi´s footprint on the global market.”
    “We have high expectations and consider the agreement to have a high volume potential,” he concluded.

    To contact our editorial team please email us at editorial@cnsmedia.com


    Keyword Tags

    Probi Ipsen Sign Primary Care Distribution probiotic strain LP299V capsules IBS dietary supplement

    Related Articles

    Date Popularity
    Woman looks at phone, supplement bottles next to her.

    PACKAGING & TECHNOLOGY NEWS

    Probi to reward customers for recycling by partnering with Bower mobile application

    03 May 2024 --- Swedish and Norwegian customers of the multinational probiotic R&D company Probi, based in Sweden, will soon be able to get a deposit back for their... Read More

    Girl takes a pill while looking out of a sunlit window.

    NUTRITION & HEALTH NEWS

    Supplement innovations: Convenient formats, holistic health offerings and science-backed ingredients

    25 Apr 2024 --- Consumer demand for sustainable clean label and natural ingredients that offer multifunctional and holistic health options for areas such as stress... Read More

    A woman looks through a microscope in a lab.

    BUSINESS NEWS

    Beyond The Headlines: Clasado Biosciences hits scientific milestone, MycoTechnology’s truffle-based sweetener

    19 Apr 2024 --- This week in nutrition news, Clasado Biosciences’ Bimuno GOS (galacto-oligosaccharide) ingredient hit a scientific milestone. At the same time,... Read More

    Four researchers in a lab evaluating the effect of synbiotics.

    NUTRITION & HEALTH NEWS

    Latest research supports the synergistic effects of Clasado Biosciences and Probi synbiotic

    26 Mar 2024 --- New research finds a synergistic effect of a synbiotic by Clasado Biosciences and Probi — combining Clasado’s prebiotic Bimuno GOS... Read More

    A woman stands next to a bunch of servers while checking her laptop.

    NUTRITION & HEALTH NEWS

    Pioneering the future of nutrition: Lallemand Health Solutions’ tech-driven approach

    05 Feb 2024 --- Digitalization, next-generation technologies and scientific advancements are set to shake up the supplement and nutraceutical industry in the coming... Read More

    More Articles

    trans